Healthcare of Ontario Pension Plan Trust Fund Has $78.64 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 59.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 155,646 shares of the company's stock after acquiring an additional 58,064 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned about 0.19% of IDEXX Laboratories worth $78,635,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in IDXX. American Century Companies Inc. raised its position in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after acquiring an additional 177,226 shares during the last quarter. International Assets Investment Management LLC increased its holdings in IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after purchasing an additional 527,460 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in IDEXX Laboratories by 13.1% in the second quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock valued at $249,855,000 after purchasing an additional 59,519 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in IDEXX Laboratories by 4.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company's stock valued at $205,163,000 after buying an additional 15,521 shares during the period. Finally, Clearbridge Investments LLC boosted its holdings in IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock worth $171,891,000 after buying an additional 308,493 shares during the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Up 1.1 %

Shares of IDEXX Laboratories stock traded up $4.44 during trading on Wednesday, reaching $421.76. The stock had a trading volume of 486,187 shares, compared to its average volume of 506,477. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $34.54 billion, a price-to-earnings ratio of 40.24, a P/E/G ratio of 3.74 and a beta of 1.36. The stock has a fifty day moving average price of $457.31 and a two-hundred day moving average price of $479.47. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analysts' expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.53 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Piper Sandler reaffirmed a "neutral" rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. JPMorgan Chase & Co. lowered their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research report on Thursday, October 10th. Finally, Barclays decreased their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.